Status:
NOT_YET_RECRUITING
Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients
Lead Sponsor:
Assiut University
Conditions:
Metastatic Breast Cancer
Eligibility:
All Genders
Brief Summary
Aim of the study to assess the neutropenia induced by Palbociclib in patient receiving Palbociclib in combination with hormonal treatment as first-line therapy in metastatic hormone receptor- positive...
Detailed Description
Palbociclib is an orally active cyclin-dependent kinase (CDK) and is considered the standard treatment for hormone receptor (HR)-positive, (HER) negative metastatic breast cancer. The PALOMA studies'...
Eligibility Criteria
Inclusion
- Histological pathological confirmation of primary breast cancer or metastatic disease.
- Hormonal receptor-positive, HER2 negative.
- Metastatic breast cancer at presentation (Den novo) or recurrent.
- Patients did not receive any previous systemic therapy for metastatic disease.
- Performance status (ECOG) 0-2.
Exclusion
- Patient with co-morbidity
- Pregnant and breast lactating women
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT06076772
Start Date
November 1 2023
End Date
December 1 2026
Last Update
October 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asmaa Imam Ahmed
Al Madīnah, AL, Saudi Arabia, 11564